February 28, 2018 / 1:04 AM / 10 months ago

BRIEF-Valeant Announces Licensing Agreement With Kaken Pharma For Psoriasis Treatment

Feb 27 (Reuters) - Valeant:

* ANNOUNCES LICENSING AGREEMENT WITH KAKEN PHARMACEUTICAL CO., LTD. TO DEVELOP AND COMMERCIALIZE NEW CHEMICAL ENTITY FOR PSORIASIS

* ‍UNDER TERMS OF LICENSING AGREEMENT, KAKEN GRANTED TO CO EXCLUSIVE LICENSE TO DEVELOP AND COMMERCIALIZE TOPICAL PRODUCTS CONTAINING KP-470​

* ‍WILL HAVE RIGHTS TO DEVELOP AND COMMERCIALIZE PRODUCTS WITH KP-470 IN UNITED STATES, CANADA, AND WESTERN AND EASTERN EUROPE​

* ‍KAKEN TO RECEIVE UPFRONT CASH PAYMENT AND HAS POTENTIAL TO RECEIVE CERTAIN DEVELOPMENT-BASED MILESTONE PAYMENTS

* ‍ADDITIONALLY, KAKEN WILL RECEIVE ROYALTIES ON VALEANT’S NET SALES OF PRODUCTS​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below